Orthopediatrics (KIDS) EBITDA (2016 - 2026)

Orthopediatrics (KIDS) has 11 years of EBITDA data on file, last reported at -$8.3 million in Q1 2026.

• On a quarterly basis, EBITDA rose 24.1% year-over-year to -$8.3 million in Q1 2026; TTM through Mar 2026 was -$36.6 million, a 0.89% decrease from a year earlier, with the FY2025 full-year figure at -$39.2 million, down 12.08% from the prior year.
• EBITDA for Q1 2026 stood at -$8.3 million, down from -$8.2 million in the prior quarter.
• Over the last five years, EBITDA for KIDS reached as high as -$3.7 million in Q2 2022 and fell as low as -$14.1 million in Q4 2024.
• Historically, EBITDA has averaged -$7.9 million across 5 years, with a median of -$8.2 million in 2025.
• Across the five-year window, EBITDA plunged 91.03% in 2022 and jumped 41.86% in 2025, its largest moves.
• Year by year, EBITDA stood at -$8.3 million in 2022, then climbed by 2.92% to -$8.1 million in 2023, then tumbled by 74.25% to -$14.1 million in 2024, then soared by 41.86% to -$8.2 million in 2025, then dropped by 1.99% to -$8.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$8.3 million in Q1 2026, -$8.2 million in Q4 2025, and -$9.4 million in Q3 2025.